Atara Biotherapeutics Inc (ATRA)
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing therapies for patients with cancer and autoimmune disease in the United States and internationally. Its clinical pipeline includes tab-cel (tabelecleucel), a T-cell immunotherapy program in Phase 3 testing for Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease and other EBV-driven conditions. The company is also advancing ATA3219, an allogeneic CAR T therapy designed to target CD19 for use in B-cell malignancies and autoimmune diseases. Atara Biotherapeutics maintains research collaborations with Memorial Sloan Kettering Cancer Center and the Council of the Queensland Institute of Medical Research. Incorporated in 2012, the company is headquartered in Thousand Oaks, California, and its common stock trades on NASDAQ under the ticker ATRA.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ATRA
|
$8.51
|
-4.7% Downside
|
Fair
|
$13.67
|
53.0% Upside
|
Bargain
|
Fair
|
0.0%
|
October 29, 2026
|
14.5x
|
89.637 M
|
89.643 M
|
9.5%
|
46.1%
|
-135.3
|
131.2%
|
